Výsledky vyhledávání - "John Sandbach"

Elektronická kniha

Soul Journey Through the Tarot : Key to a Complete Spiritual Practice

Autor: John Sandbach

Integrating numerology, astrology, Kabbalah, and the contemplative life• Connects the traditional, symbolic, psychological, alchemical, astrological, and numerological meanings of each of the 78 cards of the Tarot to its deepest meaning, the one cl

Zobrazit plný text záznamu

Phase III Multicenter Trial of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel Compared With Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel As Adjuvant Therapy for Women With High-Risk Breast Cancer

Autor: John D. Hainsworth, John Pippen, Neil Senzer, Lina Asmar, John Sandbach, F. Anthony Greco, Svetislava J. Vukelja, Scot Sedlacek, David M. Loesch, Kristi J. McIntyre, Manuel Modiano, Kristi A. Boehm, Feng Zhan, Howard A. Burris, Deborah Lindquist, Frankie A. Holmes, Nicholas J. Robert, Stephen E. Jones, Joanne L. Blum

Publikováno v: Journal of Clinical Oncology. 28:2958-2965

Purpose This study compared disease-free survival (DFS) obtained with two different regimens of adjuvant therapy in high-risk breast cancer. Methods Women (who had performance status [PS] of 0 to 1) with operable, histologically confirmed, stage I to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::918360d9aea45dbdf9736d163d90f0ca
https://doi.org/10.1200/jco.2009.24.1000

Zobrazit plný text záznamu

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735

Publikováno v: Journal of Clinical Oncology. 27:1177-1183

Purpose We previously reported that four cycles of docetaxel/cyclophosphamide (TC) produced superior disease-free survival (DFS) compared with four cycles of doxorubicin/cyclophosphamide (AC) in early breast cancer. Older women are under-represented

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfed7b530e156802494601c0acf79de8
https://doi.org/10.1200/jco.2008.18.4028

Zobrazit plný text záznamu

Results of a Phase II study of weekly docetaxel and carboplatin in Stage IIIB (with effusion) or Stage IV non-small cell lung cancer patients age ≤65 and performance status 2

Autor: Mark Vellek, Paul Conkling, Des Ilegbodu, Reginald Brooker, Deborah L. Lindquist, John Sandbach, Lina Asmar, Charles Weissman

Publikováno v: Lung Cancer. 52:313-317

This study explores if advanced NSCLC patients with ECOG PS 2 and age

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f29770244e07ffb41bc8806d48bf9119
https://doi.org/10.1016/j.lungcan.2006.01.001

Zobrazit plný text záznamu

A multicenter, Phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma

Autor: Russell F. DeVore, Daniel L. Wolf, Gary L. Elfring, Langdon L. Miller, John Sandbach, John D. Hainsworth, Mace L. Rothenberg, Richard Pazdur, John S. Macdonald, Daniel D. Von Hoff, Saul E. Rivkin, J. Scott Mohrland, Charles E. Geyer, V D O John Cox

Publikováno v: Cancer. 85:786-795

BACKGROUND This multicenter, Phase II trial was performed to evaluate the antitumor activity and toxicity of irinotecan (CPT-11) in patients with metastatic colorectal carcinoma that had recurred or progressed after 5-fluorouracil (5-FU)-based chemot

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::487147fd80e0806209145826092b62a1
https://doi.org/10.1002/(sici)1097-0142(19990215)85:4<786::aid-cncr5>3.0.co

Zobrazit plný text záznamu

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 24(34)

PurposeThe combination of doxorubicin and cyclophosphamide (AC) is a standard adjuvant chemotherapy regimen. Studies of docetaxel and cyclophosphamide (TC) in metastatic breast cancer (MBC) showed promise in MBC. In 1997, we initiated a randomized ad

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0427b29e7ee172a6d2d7aa5b9a86c683
https://pubmed.ncbi.nlm.nih.gov/18366954

Zobrazit plný text záznamu

A Phase II study of gemcitabine plus zoledronic acid in subjects with Stage IV pancreatic cancer

Autor: Michael A. Monticelli, J. V. Cox, Kristi A. Boehm, Marcus A. Neubauer, John Sandbach, Thomas H. Cartwright, Des Ilegbodu, Lina Asmar, D. McCollum

Publikováno v: Journal of Clinical Oncology. 24:14002-14002

14002 Background: Gemcitabine, the standard chemotherapy for advanced pancreatic cancer (APC), produces low response rates and short time to progression. Preclinical studies suggest that zoledronic acid inhibits pancreatic cell lines by interfering w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3f841753d8c25595ceddc19d4b5dfa21
https://doi.org/10.1200/jco.2006.24.18_suppl.14002

Zobrazit plný text záznamu

A phase II study of weekly docetaxel and carboplatin in stage IIIB (with effusion) or stage IV non-small cell lung cancer patients age <65 and performance status 2

Autor: R. Brooker, Lina Asmar, John Sandbach, Charles Weissman, Des Ilegbodu

Publikováno v: Journal of Clinical Oncology. 22:7276-7276

7122 Background: Primary goals of therapy for advanced non-small cell lung cancer (ANSCLC) are an increased survival time, palliation of symptoms, and prolonged time to progression (TTP). This study was designed to explore if ANSCLC patients (pts) wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2d06ca7b1d4273ecf0a1aa9907c1f0ff
https://doi.org/10.1200/jco.2004.22.90140.7276

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání